DUBLIN, June 26, 2023- Kpesa "Azụmaahịa ọgwụ Peptide amachibidoro - nyocha zuru ụwa ọnụ na mpaghara: lekwasị anya na ụdị Peptide, ngwaahịa na nyocha mpaghara - nyocha na amụma, 2024-2040".
Mgbe mmalite ahịa mbụ nke ọgwụ peptide amachibidoro nke mbụ, a na-atụ anya na ahịa ọgwụ amachibidoro zuru ụwa ọnụ ga-eto site na 2024 ruo 2040. A na-atụ anya nha ahịa ahụ iru $ 60M na 2024 na $ 17.38B na 2040, yana CAGR nke 38.94% karịa. oge amụma 2025-2040.
A na-atụ anya ka ahịa ọgwụ peptide amachibidoro zuru ụwa ọnụ ga-enweta nnukwu uto n'oge amụma site na 2025 ruo 2040, nke na-ebute nnukwu akụkụ site na nkwa nke ọhụụ ọhụrụ amachibidoro pipeline peptide nke na-ejedebeghị na ebumnuche nnabata.Ọganihu na teknụzụ kemịkalụ, ọganihu na azụmaahịa nke ọgwụgwọ peptide synthetic na afọ ndị na-adịbeghị anya, na ọnụ ahịa dị ọnụ ala nke biomolecules ndị a nwetara na ọrịa dị iche iche bụ ihe ndị ọzọ na-enye aka na uto a tụrụ anya n'oge amụma.
A na-eme nyocha nke mmetụta dị mkpirikpi na ogologo oge na ihe ndị na-emetụta ahịa nke ukwuu, ya bụ, ndị ọkwọ ụgbọala, ihe mgbochi na ohere.Ntụle oge dị mkpirikpi na-atụle oge 2020-2025 na nyocha ogologo oge na-atụle oge 2026-2040.
Isi mmepe na atumatu ụfọdụ ndị isi egwuregwu n'ahịa a nakweere esonyela na nyocha nyocha mmetụta.Na mgbakwunye, a na-enyocha mmepe ndị a dị mkpa iji ghọta ohere n'ọdịnihu maka ijikọ teknụzụ dị elu iji nweta nsonaazụ dị elu.Tụkwasị na nke ahụ, a na-eburukwa n'uche nkwenye na mmalite nke ụlọ ọrụ na ụlọ ọrụ patent mgbe ị na-enyocha ike nke ahịa zuru ụwa ọnụ maka ọgwụ peptide na-egbochi peptide.
Ihe ndị na-achọsi ike na ihe mgbochi Ndị a bụ ihe ndị a na-achọ maka ahịa Peptide Dependence Inhibitors zuru ụwa ọnụ:
4 Nlebaanya Ahịa 4.1 Okwu Mmalite 4.1.1 Ọdịdị na Nhazi nke Peptides amachibidoro 4.1.2 Ụdị Peptides amachibidoro 4.2 Evolution nke Peptides machibidoro 4.3 Mmepe nke Peptides machibidoro dịka ọgwụ 4.4 4.4 nwere ike ịgwọ ọrịa mpaghara 4.5 isi ihe dị mkpa mpaghara 4.5. ) ) 4.7 Isi ụlọ ọrụ usoro n'okporo ụzọ mmeghe 4.8 Isi ụlọ ọrụ na-emekarị - ọganihu nkà na ụzụ 4.9 Ọnụ ahịa ahịa ugbu a na ike uto, ijeri USD, 2024-2040 na mmeghari maka ụlọ ọrụ na-emepụta ọgwụ peptide amachibidoro.
5 Ngwongwo nke peptides conformationally restricted 5.1 Njirimara nke conformationally restricted peptides 5.2 Synthesis of restricted peptides 5.2.1 Chemical ligation of peptides and bridging 5.2.2 Chemical ligation of peptides to scaffolds (CLIPS) 5.5.2.2. nchọpụta (5.2.5 Liquid-Phase Peptide Synthesis (LPPS) 5.2.6 Solid-Phase Peptide Synthesis (SPPS) 5.3 Ọganihu na teknụzụ Peptide 5.3.1 Peptide Synthesis Iji Microfluidics 5.3.2 Ngwakọta Peptide siri ike na Ngosipụta Peptide4. Họrọ Sistemu
6 Data Industry Data 6.1 Overview 6.2 Okwu nwere ụzọ nnabata usoro iwu maka Peptides amachibidoro 6.3 Usoro nchịkwa maka Peptides amachibidoro 6.4 US Regulatory Requirements and Structure 6.4.1 Clinical Trial Ikike 6.4.2 Ikike Ịre ahịa 6.4.2 FDA.4. iwu 6.5 European iwu chọrọ na framework 6.5.1 EMA ikike ngwa usoro 6.5.2 Centralized usoro 6.5.3 Decentralized usoro 6.5.4 Mutual nnabata usoro 6.5.5 National usoro 6.6 Iwu chọrọ na frameworks na Asia-Pacific mpaghara 6.6.1 Ihe achọrọ na nhazi iwu na Japan 6.7 ndapụta nkwụghachi ụgwọ 6.7.1 Ọnọdụ nkwụghachi ụgwọ ọrịa autoimmune 6.7.2 Ọnọdụ nkwụghachi ọrịa kansa 6.7.3 ọnọdụ nkwụghachi ọrịa na-adịghị ahụkebe
7 Market Dynamics 7.1 Analysis Analysis 7.2 Market Factors 7.2.1 Mmụba njikọ njikọ na nnabata cellular 7.2.2 Mmepe nke Mmachi Synthetic Ụzọ 7.2.3 Mmachi nke Peptides Conventional 7.2.4 Mmụba na ego ọha na eze na nkeonwe 7.2.7. .4 .2 Ego site n'aka ụlọ ọrụ ndị edepụtara 7.2.4.3 Ego site na ụlọ ọrụ ọha na eze 7.3 mmachi ahịa 7.3.1 Ịba ụba asọmpi maka ihe ọmụmụ ihe ọmụmụ 7.3.2 ihe ize ndụ nke mmetụta immunogenic na njirimara sub-ezigbo nke ADME 7.4 Oghere ahịa 7.4.1 Obere peptides na nchọpụta ọgwụ 7.4.2 Ngwa dị iche iche ụjọ usoro na ọrịa cancer
8 Odida obodo asọmpi 8.1 Nlebanya nke mpaghara asọmpi 8.1.1 Mmepe isi 8.1.2 Ọrụ nchịkwa na nke iwu 8.1.3 Njikọta na nnweta 8.1.4 Ọrụ mmekọrịta 8.1.5 Ọrụ ego 8.1.6 mmepe ụlọ ọgwụ
9 Ahịa zuru ụwa ọnụ nke na-egbochi ọgwụ peptide ọgwụ (site na ntụzịaka), nde USD, 2024–2040 9.1 Nnwale Clinical maka igbochi ọgwụgwọ Peptide 9.1.1 Usoro ọgwụgwọ nwere ike ịbụ Phase II II) 9.1.2.3 arụmọrụ, nchekwa, na data nnabata (Nhazi 1) .2.4 Ọmụmụ ihe na-abụghị nke BT5528 9.1.3 PN-9439.1.3.1 Product Okwu Mmalite 9.1.3.2 Nkà mmụta ihe (Phase 2) 9.1.3.3 Ịrụ ọrụ, nchekwa na data nnabata (Oge II) 9.1.4 PN-23.19. Product1. 4.2 Ọmụmụ ihe ọmụmụ (Phase IIb) 9.1.4.3 Ịrụ ọrụ, nchekwa na data nkwụsịtụ (Phase IIb) 9.1.5 Rusfertide (PTG-300) 9.1.5.1 Product overview 9.1.5.2 Ọmụmụ ihe (usoro II) 9.1.5.3. data tolerability (Phase IIa) 9.1.6 Pụrụ Igbo nke III ọgwụ 9.1.7 Zilukoplan (RA101495) 9.1.7.1 Product nchịkọta 9.1.7.2 Nhazi ọmụmụ (Phase III) 9.1.7.3 arụmọrụ, nchekwa na ndidi data (9.1.7) . Pharmacokinetic na pharmacodynamic profaịlụ nke Zilucoplan (Phase I) 9.1.8 Rusfertide (PTG- 300) 9.1.8.1 Product nchịkọta 9.1.8.2 Ọmụmụ imewe (Phase III) 9.1.8.3 arụmọrụ, nchekwa na tolerability data (Nhazi II) nyocha (9.2). mgbanwe mmepe nke ahịa ụwa maka ọgwụ peptide amachibidoro, nde USD, 2024-2040 ịga nke ọma 9.2.2.2 Ọnụ nke mmepụta API (CDMO)
10 Ahịa zuru ụwa ọnụ maka ọgwụ nwere oke peptide action (site na ụdị peptide), US$ mln, 2024-2040 jikọtara peptide (DRP))
11 Ahịa zuru ụwa ọnụ maka ọgwụ peptide amachibidoro (site na ngwaahịa nwere ike), USD, 2024-2040 (RA101495) 11.1.2.1 mmepụta API (ụlọ) 11.1.2.2 API chọrọ amụma maka 2024-2040 11.1.3 Rusfertide.31 (PT-1) .3.1 API Mmepụta (Mpụpụ) Ọnụ 11.1.4 PN-94311.1.4.1 API Mmepụta (Mpụpụ) 11.1.4.2 API Amụma Amụma 2024-2040
Oge nzipu: Jul-06-2023